UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use

PloS one, 2014-03, Vol.9 (3), p.e92146-e92146

2014

Volltextzugriff (PDF)

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study

PLoS medicine, 2016-12, Vol.13 (12), p.e1002200-e1002200

2016

Volltextzugriff (PDF)

Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation

Proceedings of the National Academy of Sciences - PNAS, 2012-09, Vol.109 (37), p.14912-14917

2012

Volltextzugriff (PDF)

Pharmacological validation of TDO as a target for Parkinson’s disease

The FEBS journal, 2021-07, Vol.288 (14), p.4311-4331

2021

Volltextzugriff (PDF)

A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets

British journal of pharmacology, 2012-06, Vol.166 (3), p.858-876

2012

Volltextzugriff (PDF)

Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158

Journal of structural biology. X, 2020-01, Vol.4, p.100014-100014, Article 100014

2020

Volltextzugriff (PDF)

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0

Frontiers in immunology, 2021-01, Vol.11, p.609490-609490

2021

Volltextzugriff (PDF)

Ruthenium-Catalyzed Olefin Metathesis in Ionic Liquids

Organic letters, 2001-11, Vol.3 (23), p.3785-3787

2001

Volltextzugriff (PDF)

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

PloS one, 2015-05, Vol.10 (5), p.e0125021

2015

Volltextzugriff (PDF)

LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma

Journal of hepatology, 2023-01, Vol.78 (1), p.142-152

2023

Volltextzugriff (PDF)

Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance

Journal of molecular biology, 2017-02, Vol.429 (4), p.574-586

2017

Volltextzugriff (PDF)

TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2609-2617

2017

Volltextzugriff (PDF)

Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity

Journal of molecular biology, 2017-07, Vol.429 (14), p.2211-2230

2017

Volltextzugriff (PDF)

Mapping Arginase Expression with 18 F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino Acids

Journal of Nuclear Medicine, 2021-08, Vol.62 (8), p.1163-1170

2021

Volltextzugriff (PDF)

Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R‐Spine

Angewandte Chemie International Edition, 2017-05, Vol.56 (19), p.5363-5367

2017

Volltextzugriff (PDF)

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination

Frontiers in oncology, 2024-08, Vol.14

2024

Volltextzugriff (PDF)

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017

Molecular cancer therapeutics, 2019-02, Vol.18 (2), p.470-481

2019

Volltextzugriff (PDF)

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites

Oncotarget, 2020-12, Vol.11 (49), p.4570-4581

2020

Volltextzugriff (PDF)

Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies

Neuro-oncology advances, 2023-01, Vol.5 (1), p.vdad073-vdad073

2023

Volltextzugriff (PDF)

Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

PloS one, 2015-05, Vol.10 (5), p.e0125021

2015

Volltextzugriff (PDF)

High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes

Journal of biomolecular screening, 2014-10, Vol.19 (9), p.1266-1274

2014

Volltextzugriff (PDF)

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

Oncotarget, 2017-06, Vol.8 (24), p.38309-38325

2017

Volltextzugriff (PDF)

Abstract 2646: The unique binding mode of NTRC 0066-0, a novel inhibitor of the spindle assembly checkpoint kinase TTK (Mps1), leads to long target residence time and potent antitumor activity

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2646-2646

2016

Volltextzugriff (PDF)

Synthetic heparin derivatives as new anticoagulant drugs

Drug discovery today, 2005-06, Vol.10 (11), p.769-779

2005

Volltextzugriff (PDF)

High-Throughput Fluorescence-Based Activity Assay for Arginase-1

SLAS discovery, 2020-10, Vol.25 (9), p.1018-1025

2020

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(64)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(19)
Humans
(16)
Physical Sciences
(9)
Biochemistry & Molecular Biology
(8)
Chemistry
(8)
Animals
(7)
Cell Line, Tumor
(6)
Cell Proliferation - Drug Effects
(6)
Inhibitors
(6)
Mutation
(6)
Pharmacology & Pharmacy
(6)
Protein Kinase Inhibitors - Pharmacology
(6)
Cancer
(5)
Kinases
(5)
Multidisciplinary Sciences
(5)
Oncology
(5)
Science & Technology - Other Topics
(5)
Tryptophan
(5)
Biological And Medical Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study

Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation

Pharmacological validation of TDO as a target for Parkinson’s disease

A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets

Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0

Ruthenium-Catalyzed Olefin Metathesis in Ionic Liquids

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma

Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance

TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers

Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity

Mapping Arginase Expression with 18 F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino Acids

Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R‐Spine

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites

Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies

Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

Abstract 2646: The unique binding mode of NTRC 0066-0, a novel inhibitor of the spindle assembly checkpoint kinase TTK (Mps1), leads to long target residence time and potent antitumor activity

Synthetic heparin derivatives as new anticoagulant drugs

High-Throughput Fluorescence-Based Activity Assay for Arginase-1

Suchergebnisse filtern